WebAlthough direct-acting oral anticoagulants (DOACs) have widespread first-line use for treatment and prevention of venous thromboembolism (VTE), uncertainty remains regarding their efficacy and safety in patients with obesity. We reviewed available data for use of DOACs for VTE treatment and preventi … WebObjective: To review literature on the use of direct-acting oral anticoagulants (DOACs) in patients with high body weight (BW) and/or high body mass index (BMI) and to make …
An update on applications and limitations of direct oral …
WebApr 7, 2024 · The DOACs are an effective alternative to vitamin K antagonist (VKA) and provide an alternative oral approach without the need for parenteral medications. ... (BMI), were hypertensive, and/or suffered from diabetes. The study demonstrated that a high ratio of hospitalized VTE patients have long hospital LOS (≥7 days). Most of the patients ... WebWe assessed the comparative effectiveness and safety of DOACs with warfarin for the treatment of VTE among obese patients. This multi-center retrospective cohort study included adults with a BMI ≥ 35 kg/m 2 or weight ≥ 120 kg prescribed either DOAC (apixaban, dabigatran, edoxaban, rivaroxaban) or warfarin for a VTE diagnosis. The … hemoglobin a1c 8.4
Efficacy and Safety of Direct Oral Anticoagulants for …
Webfor either an abnormally high or low BMI. The impact of obesity (BMI > 30 kg/m2) on treatment with DOACs is variable and conflicting. Peak apixaban concentrations and total drug exposure were found to be 31% and 23% lower, respectively, in healthy patients weighing > 120 kg with a BMI $ 30 kg/m2 compared with those in a WebBackground: The International Society on Thrombosis and Haemostasis recommends avoiding the use of direct oral anticoagulants (DOACs) in patients with a body mass index (BMI) greater than 40 kg/m 2 or weight greater than 120 kg. Hypothesis: Higher BMI is associated with altered pharmacokinetics which may affect the safety and effectiveness … WebDec 11, 2024 · An analysis of ROCKET‐AF (Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation) with 5206 patients with a BMI ≥30 kg/m 2 showed a lower risk of stroke in these patients with obesity compared … hemoglobin a1c 8.0